Bristol-Myers Squibb(US:BMY)2025-10-30 12:00Financial Performance - Global net sales reached approximately $12.2 billion, a 3% year-over-year increase, or 2% excluding foreign exchange impacts[11] - The Growth Portfolio net sales increased by 18%, or 17% excluding foreign exchange impacts[11] - Q3 2025 GAAP Earnings Per Share (EPS) was $1.08, while Non-GAAP EPS was $1.63, including a ($0.20) charge from Acquired IPR&D and licensing income[13] - The company is narrowing Non-GAAP EPS guidance to $6.40 - $6.60 and raising total revenues to approximately $47.5 - $48.0 billion[14] Product Performance - Opdivo global net sales were $2.532 billion, a 7% year-over-year increase, or 6% excluding foreign exchange impacts[33] - Eliquis global net sales were $3.746 billion, a 25% year-over-year increase, or 23% excluding foreign exchange impacts[44] - Reblozyl global net sales were $675 million, a 25% year-over-year decrease, or 25% decrease excluding foreign exchange impacts[39] - Breyanzi global net sales were $615 million, a 37% year-over-year increase, or 37% increase excluding foreign exchange impacts[39] Strategic Initiatives - The company is on track to pay down approximately $10 billion of debt by the end of Q2 2026, with approximately $6.7 billion achieved as of Q3 2025[55] - The company has approximately $5 billion share repurchase authorization remaining as of September 30, 2025[55]